Chronické cholestatické jaterní choroby, primární biliární cholangitida a primární sklerozující cholangitida
[Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis]
Language Czech Country Czech Republic Media print
Document type Journal Article
PubMed
32942866
PII: 123755
- Keywords
- biliary cholangitis, cholangitis, cholestasis, diagnostics, sclerosing cholangitis, treatment,
- MeSH
- Liver Cirrhosis, Biliary * complications diagnosis therapy MeSH
- Cholestasis * pathology MeSH
- Ursodeoxycholic Acid MeSH
- Humans MeSH
- Cholangitis, Sclerosing * complications diagnosis therapy MeSH
- Bile Ducts pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Ursodeoxycholic Acid MeSH
Cholestasis is defined as hepatocyte and cholangiocyte bile excretion failure or failure of bile transport to the duodenum. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis as chronic progressive cholestatic diseases are the common reasons of chronic cholestasis. Altogether with cholestatic laboratory picture the pruritus, liver osteodystrophy and fatigue are associated symptoms in both diseases. All associated symptoms and complications are needed to be diagnosed and treated early. In case of liver cirrhosis complicatons of accompanied portal hypertension should be treated and liver transplantation must be considered in all those patients. Diagnosis of PBC is based on cholestatic laboratory features, animitochondrial antibody positivity or typical histological patern. Most patients are asymptomatic in time of diagnosis. First line therapy is ursodeoxycholic acid. In case of first line therapy failure, the prognosis is unfavourable. In this case, second line therapy must be considered. In case of PSC the diagnosis is based on MRCP finding mainly, laboratory test and liver biopsy in some cases. Progressive inflamatory and fibrosing impairment affecting intrahepatic and extrahepatict biliary ducts and strong association with inflamatory bowel disease, especially ulcerative colitis is typical for PSC. Endoscopic therapy with dilatation of dominant structure is crucial. The effect of pharmacotherapy is still being discussed and ursodeoxycholic acid could be used. During follow up patients are in the risk of bacterial cholangitis and malignant tumor development (cholangiogenic and colorectal carcinoma mainly). In PSC patients the severe pruritus and reccurent bacterial cholangitis could be an indication for the liver transplantation.